BioCentury | Mar 10, 2003
Finance

Ebb & Flow

...valuation of either company. Perhaps that's because the disgruntled shareholder was unsuccessful at blocking the Sequana-Arris...
BioCentury | Jul 24, 2000
Finance

Restarting the IPO engine

...was Sequana, which was conducting genetic studies in the isolated population of Tristan da Cunha. Sequana...
...now known as Axys (AXPH). But AXPH subsequently sold off the population genomics side of Sequana's...
BioCentury | Sep 13, 1999
Emerging Company Profile

Kiva Genetics: Clinical grade genetic analysis

...on your own nickel is a model that was abandoned by Millennium Pharmaceuticals Inc. and Sequana Therapeutics Inc....
BioCentury | Aug 23, 1999
Finance

Divided we stand

...week. Lampert has been through this movie before. In December 1997, he unsuccessfully opposed the Arris-Sequana...
BioCentury | Aug 2, 1999
Strategy

Axys: Selective disacquisition

...Axys Pharmaceuticals Inc. - then Arris Pharmaceutical Corp. - acquired toolkit company Sequana Therapeutics Inc. in 1997 for...
...AXPH announced that it will sell its positional cloning programs located in San Diego, where Sequana...
...cloning programs, which represented 75 percent of Sequana's operations. In the meantime, AXPH is keeping Sequana's...
BioCentury | Mar 1, 1999
Tools & Techniques

Founder population studies

...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana...
...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana...
BioCentury | Oct 5, 1998
Finance

Third Quarter Stocks: If not now, . . .

...said. Axys (AXPH, South San Francisco, Calif.) merged with Khepri Pharmaceuticals in 1995 and with Sequana...
BioCentury | Jun 1, 1998
Analyst Picks & Changes

Analyst picks & changes

...a recent low above $6, driven by disgruntled shareholders who disagreed with the acquisition of Sequana...
BioCentury | May 26, 1998
Company News

Axys, Glaxo Wellcome Inc. deal

...obesity and Type II non-insulin dependent diabetes. The collaboration began in 1994 between Glaxo and Sequana Therapeutics Inc....
BioCentury | Apr 20, 1998
Company News

Axys board of directors update

...San Francisco, Calif. Business: Autoimmune/Inflammation, Drug discovery Departing: Kevin Kinsella, former president and CEO of Sequana Therapeutics Inc....
Items per page:
1 - 10 of 87
BioCentury | Mar 10, 2003
Finance

Ebb & Flow

...valuation of either company. Perhaps that's because the disgruntled shareholder was unsuccessful at blocking the Sequana-Arris...
BioCentury | Jul 24, 2000
Finance

Restarting the IPO engine

...was Sequana, which was conducting genetic studies in the isolated population of Tristan da Cunha. Sequana...
...now known as Axys (AXPH). But AXPH subsequently sold off the population genomics side of Sequana's...
BioCentury | Sep 13, 1999
Emerging Company Profile

Kiva Genetics: Clinical grade genetic analysis

...on your own nickel is a model that was abandoned by Millennium Pharmaceuticals Inc. and Sequana Therapeutics Inc....
BioCentury | Aug 23, 1999
Finance

Divided we stand

...week. Lampert has been through this movie before. In December 1997, he unsuccessfully opposed the Arris-Sequana...
BioCentury | Aug 2, 1999
Strategy

Axys: Selective disacquisition

...Axys Pharmaceuticals Inc. - then Arris Pharmaceutical Corp. - acquired toolkit company Sequana Therapeutics Inc. in 1997 for...
...AXPH announced that it will sell its positional cloning programs located in San Diego, where Sequana...
...cloning programs, which represented 75 percent of Sequana's operations. In the meantime, AXPH is keeping Sequana's...
BioCentury | Mar 1, 1999
Tools & Techniques

Founder population studies

...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana...
...genetic studies (including use of the Tristan da Cunha population) through its 1998 acquisition of Sequana...
BioCentury | Oct 5, 1998
Finance

Third Quarter Stocks: If not now, . . .

...said. Axys (AXPH, South San Francisco, Calif.) merged with Khepri Pharmaceuticals in 1995 and with Sequana...
BioCentury | Jun 1, 1998
Analyst Picks & Changes

Analyst picks & changes

...a recent low above $6, driven by disgruntled shareholders who disagreed with the acquisition of Sequana...
BioCentury | May 26, 1998
Company News

Axys, Glaxo Wellcome Inc. deal

...obesity and Type II non-insulin dependent diabetes. The collaboration began in 1994 between Glaxo and Sequana Therapeutics Inc....
BioCentury | Apr 20, 1998
Company News

Axys board of directors update

...San Francisco, Calif. Business: Autoimmune/Inflammation, Drug discovery Departing: Kevin Kinsella, former president and CEO of Sequana Therapeutics Inc....
Items per page:
1 - 10 of 87